Sorilux Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8269128 MAYNE PHARMA Vacuum switch tube
May, 2026

(1 year, 10 months from now)

US8629128 MAYNE PHARMA Vitamin formulation
May, 2026

(1 year, 10 months from now)

US8263580 MAYNE PHARMA Vitamin formulation
May, 2028

(3 years from now)



Sorilux is a drug owned by Mayne Pharma Llc. It is used for treating plaque psoriasis in patients aged 4 years and older. Sorilux uses Calcipotriene as an active ingredient. Sorilux was launched by Mayne Pharma in 2010. It is is available in aerosol, foam form for topical use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 07, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Oct 06, 2013
New Indication(I-657) Sep 27, 2015
New Patient Population(NPP) Nov 05, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CALCIPOTRIENE ingredient

Market Authorisation Date: 06 October, 2010

Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older

Dosage: AEROSOL, FOAM

More Information on Dosage

SORILUX family patents

Family Patents